This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
HuntS.A., AbrahamW.T., ChinM.H., FeldmanA.M., FrancisG.S., GaniatsT.G.. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol.2005; 46: e1–e82.
2.
StaessenJ., LijnenP., FagardR., VerschuerenL.J., AmeryA.Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol.1981; 91: 457–465.
3.
PittB., ZannadF., RemmeW.J.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med.1999; 341: 709–717.
4.
PittB., RemmeW., ZannadF.. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med.2003; 348: 1309–1321.
5.
JuurlinkD.N., MamdaniM.M., LeeD.S.. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med.2004; 351: 543–551.
6.
CruzC.S., CruzL.S., DominguesG.S., SouzaC.A.New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalemia. Expert Opin Drug Saf.2005; 4: 677–688.
7.
SvenssonM., GustafssonF., GalatiusS., HildebrandtP.R., AtarD.How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?J Card Fail.2004; 10: 297–303.
8.
SchepkensH., VanholderR., BilliouwJ.M., LameireN.Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med.2001; 110: 438–441.
9.
BozkurtB., AgostonI., KnowltonA.A.Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol.2003; 41: 211–214.
10.
WithamM.D., NeilD., Gillespie, StruthersA.D.Tolerability of spironolactone in patients with chronic heart failure – a cautionary message. Br J Clin Pharmacol.2004; 58: 554–557.
11.
ShahK.B., RaoK., SawyerR., GottliebS.S.The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol.2005; 46: 845–849.
